Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NRXPW
NRXPW | US
0.02
USD0
0%
NRXPW | US
About NRXPW
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
12/03/2026
Close
0.02
Open
0.01
High
0.02
Low
0.01
NRX Pharmaceuticals Inc. a clinical-stage pharmaceutical company develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington Delaware.
View LessNRXPW | US
Risk
294.3
Sharpe
0
Luna's Score
36/100
Recommendation
Sell
Luna says (NRXPW | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
313.9%1 month
294.3%3 months
310.4%6 months
299.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
-
Debt to equity
-0.47
Debt to assets
1.63
Ent. to EBITDA
-
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-23.26M
MarketCap
269.16M
MarketCap(USD)
269.16M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-682.61
Short ratio
-
Short perc.
-
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.03
Range1M
0.04
Range3M
0.08
Volumes: Market Activity
Rel. volume
1.49
Price X volume
833.62
